FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005630002> ?p ?o ?g. }

• W2005630002 abstract "Background: Preclinical studies indicate that the dual inhibition of IGFR and mTOR may be additive or synergistic and abrogates the feedback activation of AKT due to rapamycin analog mTOR inhibitors. A phase 1 study of the mTOR inhibitor RIDA and the anti-IGFR antibody DALO demonstrated that the combination was feasible and well-tolerated at doses that were nearly those used for the two single agents. The dose limiting toxicity was stomatitis, similar to RIDA monotherapy. Preliminary signals of anti-tumor activity, including partial responses and prolonged progression free survival (PFS), were observed in ER+ advanced breast cancer (ABC), especially in high proliferation tumors (Ki67 ≥15%). Methods: The trial was a multi-center, international randomized study with PFS as the primary endpoint. Key eligibility included ABC with prior treatment with a non-steroidal aromatase inhibitor. The original phase 2 study design was a two-part, adaptive design intended to first test the combination of RIDA (30 mg by mouth daily for 5 out of every 7 days), -DALO (10 mg/kg IV weekly) against a standard agent, exemestane in Part A. Patients were stratified into high and low proliferation strata based on baseline Ki67. Following a demonstration of PFS benefit of the combination in Part A, Part B was intended to show the PFS benefit of the combination over each single agents by comparing RIDA-DALO to RIDA and DALO. Results: The study was initiated in October 2011. Accrual was suspended after the first 66 patients were randomized due to a higher than expected rate of stomatitis in the RIDA-DALO arm. Preliminary data indicated an overall incidence of any grade stomatitis was 68% (22/33 pts), and of grade 3 stomatitis was 35% (11/33 pts). In an effort to identify a more tolerable regimen, the study was amended to eliminate Part B and to evaluate two sequential reduced dose RIDA-DALO cohorts in a non-randomized design: 20mg and 10mg for 5 out of every 7 days. The dose of DALO was unchanged. Preliminary safety results of overall and grade 3 stomatitis in the 20 mg were 81.5% (22/27 pts) and 37% (10/27 pts), respectively. Although the incidence of overall stomatitis in the 10 mg cohort remained high, 88% (22/25 pts), grade 3 stomatitis was dramatically reduced to 8% (2/25 pts). Conclusion: Preliminary evaluation of safety from this phase 2 study demonstrates that the previously recommended phase 2 dose of RIDA-DALO was not tolerable. However lower doses of RIDA (10 mg) in combination with DALO appeared to be tolerable with markedly reduced rates of grade 3 stomatitis. Final results of efficacy, safety and RNA profiling analysis from the two RIDA-DALO dose cohorts as well as from the randomized portion of the study will be available at the time of the meeting. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-04." @default.
• W2005630002 created "2016-06-24" @default.
• W2005630002 creator A5002313852 @default.
• W2005630002 creator A5004300577 @default.
• W2005630002 creator A5009588391 @default.
• W2005630002 creator A5010064853 @default.
• W2005630002 creator A5017550097 @default.
• W2005630002 creator A5024350975 @default.
• W2005630002 creator A5028942861 @default.
• W2005630002 creator A5031366322 @default.
• W2005630002 creator A5035286316 @default.
• W2005630002 creator A5039881921 @default.
• W2005630002 creator A5040688902 @default.
• W2005630002 creator A5047384785 @default.
• W2005630002 creator A5048903763 @default.
• W2005630002 creator A5049358292 @default.
• W2005630002 creator A5052833964 @default.
• W2005630002 creator A5073752073 @default.
• W2005630002 creator A5076056273 @default.
• W2005630002 creator A5085797367 @default.
• W2005630002 creator A5090317977 @default.
• W2005630002 date "2013-12-15" @default.
• W2005630002 modified "2023-09-27" @default.
• W2005630002 title "Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer" @default.
• W2005630002 doi "https://doi.org/10.1158/0008-5472.sabcs13-p2-16-04" @default.
• W2005630002 hasPublicationYear "2013" @default.
• W2005630002 type Work @default.
• W2005630002 sameAs 2005630002 @default.
• W2005630002 citedByCount "1" @default.
• W2005630002 countsByYear W20056300022017 @default.
• W2005630002 crossrefType "proceedings-article" @default.
• W2005630002 hasAuthorship W2005630002A5002313852 @default.
• W2005630002 hasAuthorship W2005630002A5004300577 @default.
• W2005630002 hasAuthorship W2005630002A5009588391 @default.
• W2005630002 hasAuthorship W2005630002A5010064853 @default.
• W2005630002 hasAuthorship W2005630002A5017550097 @default.
• W2005630002 hasAuthorship W2005630002A5024350975 @default.
• W2005630002 hasAuthorship W2005630002A5028942861 @default.
• W2005630002 hasAuthorship W2005630002A5031366322 @default.
• W2005630002 hasAuthorship W2005630002A5035286316 @default.
• W2005630002 hasAuthorship W2005630002A5039881921 @default.
• W2005630002 hasAuthorship W2005630002A5040688902 @default.
• W2005630002 hasAuthorship W2005630002A5047384785 @default.
• W2005630002 hasAuthorship W2005630002A5048903763 @default.
• W2005630002 hasAuthorship W2005630002A5049358292 @default.
• W2005630002 hasAuthorship W2005630002A5052833964 @default.
• W2005630002 hasAuthorship W2005630002A5073752073 @default.
• W2005630002 hasAuthorship W2005630002A5076056273 @default.
• W2005630002 hasAuthorship W2005630002A5085797367 @default.
• W2005630002 hasAuthorship W2005630002A5090317977 @default.
• W2005630002 hasConcept C121608353 @default.
• W2005630002 hasConcept C126322002 @default.
• W2005630002 hasConcept C143998085 @default.
• W2005630002 hasConcept C168563851 @default.
• W2005630002 hasConcept C190283241 @default.
• W2005630002 hasConcept C203092338 @default.
• W2005630002 hasConcept C2775860665 @default.
• W2005630002 hasConcept C2776166826 @default.
• W2005630002 hasConcept C2776999253 @default.
• W2005630002 hasConcept C2778504769 @default.
• W2005630002 hasConcept C2779699572 @default.
• W2005630002 hasConcept C530470458 @default.
• W2005630002 hasConcept C55493867 @default.
• W2005630002 hasConcept C71924100 @default.
• W2005630002 hasConcept C86554907 @default.
• W2005630002 hasConcept C86803240 @default.
• W2005630002 hasConcept C98274493 @default.
• W2005630002 hasConceptScore W2005630002C121608353 @default.
• W2005630002 hasConceptScore W2005630002C126322002 @default.
• W2005630002 hasConceptScore W2005630002C143998085 @default.
• W2005630002 hasConceptScore W2005630002C168563851 @default.
• W2005630002 hasConceptScore W2005630002C190283241 @default.
• W2005630002 hasConceptScore W2005630002C203092338 @default.
• W2005630002 hasConceptScore W2005630002C2775860665 @default.
• W2005630002 hasConceptScore W2005630002C2776166826 @default.
• W2005630002 hasConceptScore W2005630002C2776999253 @default.
• W2005630002 hasConceptScore W2005630002C2778504769 @default.
• W2005630002 hasConceptScore W2005630002C2779699572 @default.
• W2005630002 hasConceptScore W2005630002C530470458 @default.
• W2005630002 hasConceptScore W2005630002C55493867 @default.
• W2005630002 hasConceptScore W2005630002C71924100 @default.
• W2005630002 hasConceptScore W2005630002C86554907 @default.
• W2005630002 hasConceptScore W2005630002C86803240 @default.
• W2005630002 hasConceptScore W2005630002C98274493 @default.
• W2005630002 hasLocation W20056300021 @default.
• W2005630002 hasOpenAccess W2005630002 @default.
• W2005630002 hasPrimaryLocation W20056300021 @default.
• W2005630002 hasRelatedWork W1965679184 @default.
• W2005630002 hasRelatedWork W1992277925 @default.
• W2005630002 hasRelatedWork W2002687930 @default.
• W2005630002 hasRelatedWork W2012435258 @default.
• W2005630002 hasRelatedWork W2024524048 @default.
• W2005630002 hasRelatedWork W2034466163 @default.
• W2005630002 hasRelatedWork W2043324920 @default.
• W2005630002 hasRelatedWork W2055722855 @default.
• W2005630002 hasRelatedWork W2073378249 @default.
• W2005630002 hasRelatedWork W2076670881 @default.
• W2005630002 hasRelatedWork W2092559471 @default.
• W2005630002 hasRelatedWork W2142900955 @default.
• W2005630002 hasRelatedWork W2164252571 @default.

• next